What is Trump’s new TrumpRx website and will it bring medicine prices down?
Key Takeaways
- The Trump administration is launching a new website, TrumpRx, in early 2026 for direct drug purchases.
- TrumpRx will offer prescription drugs at 'most favoured nation' (MFN) prices, similar to those paid by foreign national health services.
- Pfizer has signed on to the platform, offering discounts up to 85% for uninsured consumers and Medicaid beneficiaries.
- The goal of the initiative is to reduce prescription drug costs for American families and stop subsidizing foreign healthcare.
- The announcement led to a sharp increase in shares for the pharmaceuticals sector.
The Trump administration is set to launch a new platform called TrumpRx in early 2026, designed to allow American consumers to buy prescription drugs directly from pharmaceutical manufacturers at discounted rates. This move is intended to bring US prices closer to the 'most favoured nation' (MFN) prices paid by foreign national health services, which the administration claims currently results in US consumers subsidizing foreign healthcare costs. Pfizer has become the first pharmaceutical group to join, committing to offer discounts up to 85% for uninsured individuals and Medicaid recipients, and will also sell to the Medicaid program at reduced prices. The announcement was met with a sharp lift in pharmaceutical sector shares, suggesting a favorable market response despite the intended price reductions. Trump stated the move ends the era of global price gouging, emphasizing that the US will no longer subsidize foreign healthcare. This website launch follows a previous executive order and letters sent to pharmaceutical CEOs demanding price reductions.
